Our website uses its own and third parties cookies for a high level of user-friendliness. If you continue to browse and  use this website we will assume that you agree with the policies.

R&D

Precisesads. Molecular Reclassification to find Clinically Useful Biomarkers for Systemic Autoimmune diseases

The goal of this project is the use of the power of OMICs, and bioinformatics to identify new classifications for diseases known to share common pathophysiological mechanisms. We are investigating individuals with systemic lupus erythematosus (SLE), systemic sclerosis (SSc), Sjögren’s syndrome (Sjs), rheumatoid arthritis (RA), primary antiphospholipid syndrome (PAPS) and mixed connective tissue disease (MCTD), jointly as systemic autoimmune diseases (SADs).

http://www.precisesads.eu/

 

1st August 2017: PRECISESADS Cross Sectional Clinical Study- over 2000 patients recruited.  

PRECISESADS has now recruited over 2000 people into its pan-European cross sectional clinical study of systemic autoimmune diseases such as rheumatoid arthritis and lupus. This milestone means that the project is well on track towards its goal of recruiting a total of 2.500 people from across 9 European countries. Within the project, patients suffering with systemic autoimmune diseases and healthy people are providing blood and urine samples to undergo detailed molecular analysis at several collaborating laboratories. ‘This will allow us to gain a full molecular profile of the patients and (hopefully) allow us to cluster the patients into groups based on their molecular profile instead of their clinical symptoms,' explains project coordinator Marta Alarcón-Riquelme of GENYO in Spain. ‘This will then allow clinicians to tailor the therapies to the specific pathways to be targeted in a sort of personalised medicine.’

The project, which started in February 2014, has already fully recruited an earlier clinical study with 304 patients and analysis of this cohort is currently underway. Once completed the latest study will be used to confirm the findings of this earlier discovery work. Finally, a third cohort, which is underway and currently following 212 newly diagnosed patients over 14 months will be analysed to help understand the clinical value of the confirmed findings.

Recruitment of the last 350 patients into the latest cohort is expected to finish before mid-October.

Consortium formed by 21 academic, 2 SMEs and 5 industrial partners from 12 European countries

Funded by theEuropean Commission’s Seventh Framework Program for Research and contributions by the pharmaceutical companies participating in the project.

2014-2019